Ultra‐high combined positive score and high serum albumin are favorable prognostic biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma

Background Biomarkers that predict response to immune checkpoint inhibitor (ICI) in recurrent metastatic squamous cell carcinoma of the head and neck (RMHNSCC) are not well known. Methods We prospectively measured the combined positive score (CPS) and administered ICI to patients with RMHNSCC. Resul...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2024-02, Vol.46 (2), p.367-377
Main Authors: Saito, Yuki, Kobayashi, Kenya, Fukuoka, Osamu, Sakai, Toshihiko, Yamamura, Koji, Ando, Mizuo, Kondo, Kenji
Format: Article
Language:English
Subjects:
Albumin
B7-H1 Antigen
Biomarkers
Chemotherapy
CPS ≥90
Head & neck cancer
Head and neck carcinoma
Head and Neck Neoplasms - drug therapy
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Metastases
metastasis
Multivariate analysis
PD‐L1
Prognosis
recurrent
Serum Albumin
Squamous cell carcinoma
Squamous Cell Carcinoma of Head and Neck - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Biomarkers that predict response to immune checkpoint inhibitor (ICI) in recurrent metastatic squamous cell carcinoma of the head and neck (RMHNSCC) are not well known. Methods We prospectively measured the combined positive score (CPS) and administered ICI to patients with RMHNSCC. Results Of 51 patients, 23 patients had a CPS 3.5 (HR 0.3463, p = 0.01354) were the significant factors and plus chemotherapy (HR 0.4648, p = 0.07632) was not significant. Seven patients (14%) with CPS ≥90 and albumin >3.5 showed a 2‐year survival rate of 66. 7%. Conclusions CPS ≥90 and albumin >3.5 cases are a subgroup of RMHNSCC that respond extremely well to ICI.
ISSN:1043-3074
1097-0347
1097-0347
DOI:10.1002/hed.27576